PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing. Issues related to the funding of HHS blood and plasma awareness campaign.
Foreign entity interest: GRIFOLS S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE BIRKOFER | — |
| ANITA BRIKMAN New | — |
| THOMAS B LILBURN | — |
| DANIEL SEATON | — |
Health Issues HCR
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
Foreign entity interest: GRIFOLS S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE BIRKOFER | — |
| ANITA BRIKMAN New | — |
| THOMAS B LILBURN | — |
| DANIEL SEATON New | n/a |
Taxation/Internal Revenue Code TAX
Issues related to the continuation or change of the Orphan Drug Tax Credit.
Foreign entity interest: Grifols S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B LILBURN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.